Kiran Kumar Solingapuram Sai
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Positron-Emission Tomography | 15 | 2025 | 168 | 4.200 |
Why?
|
| Radiopharmaceuticals | 9 | 2024 | 93 | 2.150 |
Why?
|
| Brain | 11 | 2025 | 949 | 1.970 |
Why?
|
| Microtubules | 3 | 2025 | 22 | 1.680 |
Why?
|
| Glioblastoma | 5 | 2017 | 157 | 1.600 |
Why?
|
| Fluorine Radioisotopes | 4 | 2018 | 19 | 1.170 |
Why?
|
| Brain Neoplasms | 5 | 2017 | 647 | 1.120 |
Why?
|
| Tissue Distribution | 8 | 2024 | 59 | 1.010 |
Why?
|
| Neurodegenerative Diseases | 1 | 2025 | 13 | 0.930 |
Why?
|
| Insulin | 2 | 2025 | 369 | 0.910 |
Why?
|
| Animals | 22 | 2025 | 7599 | 0.900 |
Why?
|
| Administration, Intranasal | 2 | 2025 | 32 | 0.890 |
Why?
|
| Carbon Radioisotopes | 5 | 2019 | 24 | 0.780 |
Why?
|
| Mice | 11 | 2022 | 2529 | 0.750 |
Why?
|
| Substance-Related Disorders | 2 | 2022 | 131 | 0.730 |
Why?
|
| Liver Neoplasms | 1 | 2022 | 155 | 0.680 |
Why?
|
| Head and Neck Neoplasms | 1 | 2022 | 134 | 0.670 |
Why?
|
| Neoplasms | 4 | 2019 | 762 | 0.630 |
Why?
|
| Neovascularization, Pathologic | 2 | 2017 | 80 | 0.630 |
Why?
|
| Isotope Labeling | 4 | 2019 | 16 | 0.600 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2019 | 84 | 0.590 |
Why?
|
| Piperidines | 1 | 2019 | 120 | 0.580 |
Why?
|
| Cell Line, Tumor | 8 | 2019 | 727 | 0.530 |
Why?
|
| Receptors, Somatomedin | 1 | 2017 | 2 | 0.530 |
Why?
|
| Nicotine | 1 | 2019 | 177 | 0.530 |
Why?
|
| Radioligand Assay | 1 | 2017 | 18 | 0.520 |
Why?
|
| Benzopyrans | 1 | 2017 | 6 | 0.520 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2017 | 51 | 0.520 |
Why?
|
| Drug Delivery Systems | 2 | 2017 | 105 | 0.510 |
Why?
|
| Boron Compounds | 1 | 2017 | 11 | 0.510 |
Why?
|
| Neuroblastoma | 1 | 2017 | 31 | 0.510 |
Why?
|
| Pyrroles | 1 | 2017 | 52 | 0.510 |
Why?
|
| Pyrimidines | 1 | 2017 | 62 | 0.500 |
Why?
|
| Alzheimer Disease | 3 | 2025 | 302 | 0.480 |
Why?
|
| Neoplastic Stem Cells | 1 | 2017 | 98 | 0.480 |
Why?
|
| Blood-Brain Barrier | 4 | 2019 | 50 | 0.450 |
Why?
|
| Ligands | 5 | 2022 | 78 | 0.450 |
Why?
|
| Humans | 23 | 2025 | 32968 | 0.440 |
Why?
|
| Methadyl Acetate | 1 | 2014 | 1 | 0.430 |
Why?
|
| Molecular Structure | 5 | 2019 | 49 | 0.400 |
Why?
|
| Tyrosine | 1 | 2013 | 23 | 0.400 |
Why?
|
| Triazoles | 1 | 2013 | 14 | 0.400 |
Why?
|
| Alanine | 1 | 2013 | 27 | 0.400 |
Why?
|
| Molecular Probes | 1 | 2013 | 16 | 0.390 |
Why?
|
| Butyrates | 1 | 2012 | 3 | 0.380 |
Why?
|
| Phenylurea Compounds | 1 | 2012 | 10 | 0.380 |
Why?
|
| Alpha Particles | 3 | 2017 | 7 | 0.370 |
Why?
|
| PPAR alpha | 1 | 2012 | 29 | 0.370 |
Why?
|
| Glioma | 1 | 2013 | 136 | 0.360 |
Why?
|
| Male | 15 | 2025 | 19754 | 0.340 |
Why?
|
| Structure-Activity Relationship | 3 | 2019 | 78 | 0.310 |
Why?
|
| Ketones | 1 | 2008 | 11 | 0.290 |
Why?
|
| Amides | 1 | 2008 | 18 | 0.280 |
Why?
|
| Mesylates | 1 | 2007 | 1 | 0.270 |
Why?
|
| Acetanilides | 1 | 2007 | 5 | 0.270 |
Why?
|
| Glucosides | 1 | 2025 | 12 | 0.230 |
Why?
|
| Benzhydryl Compounds | 1 | 2025 | 16 | 0.230 |
Why?
|
| Mice, Inbred BALB C | 2 | 2017 | 169 | 0.220 |
Why?
|
| Thrombectomy | 1 | 2025 | 75 | 0.210 |
Why?
|
| Gallium Radioisotopes | 1 | 2024 | 3 | 0.210 |
Why?
|
| Heterocyclic Compounds, 1-Ring | 1 | 2024 | 4 | 0.210 |
Why?
|
| Heterocyclic Compounds | 1 | 2024 | 12 | 0.210 |
Why?
|
| Cations | 3 | 2008 | 10 | 0.210 |
Why?
|
| Rodentia | 1 | 2022 | 10 | 0.190 |
Why?
|
| Ascorbic Acid | 1 | 2022 | 21 | 0.190 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2025 | 1310 | 0.190 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2022 | 622 | 0.190 |
Why?
|
| Doxorubicin | 1 | 2022 | 84 | 0.180 |
Why?
|
| Primates | 1 | 2022 | 118 | 0.180 |
Why?
|
| Reactive Oxygen Species | 1 | 2022 | 165 | 0.180 |
Why?
|
| Receptors, Dopamine D3 | 2 | 2022 | 33 | 0.180 |
Why?
|
| Receptors, Dopamine D2 | 2 | 2022 | 78 | 0.170 |
Why?
|
| Rats | 2 | 2022 | 1610 | 0.170 |
Why?
|
| Glycogen Synthase Kinase 3 | 2 | 2019 | 7 | 0.170 |
Why?
|
| Macaca | 1 | 2020 | 27 | 0.170 |
Why?
|
| Actinium | 2 | 2017 | 3 | 0.170 |
Why?
|
| Capillary Permeability | 2 | 2017 | 18 | 0.170 |
Why?
|
| Papio | 1 | 2020 | 81 | 0.160 |
Why?
|
| Neurotransmitter Agents | 1 | 2019 | 26 | 0.150 |
Why?
|
| Magnetic Resonance Spectroscopy | 3 | 2008 | 88 | 0.150 |
Why?
|
| Antibodies, Bispecific | 1 | 2019 | 6 | 0.150 |
Why?
|
| Cocaine | 1 | 2022 | 253 | 0.150 |
Why?
|
| Diet, Mediterranean | 1 | 2019 | 32 | 0.150 |
Why?
|
| Female | 5 | 2025 | 20375 | 0.150 |
Why?
|
| Niacinamide | 1 | 2019 | 8 | 0.150 |
Why?
|
| Zirconium | 1 | 2018 | 2 | 0.150 |
Why?
|
| Chlorides | 1 | 2018 | 13 | 0.150 |
Why?
|
| Radioisotopes | 1 | 2018 | 6 | 0.150 |
Why?
|
| Immunoconjugates | 1 | 2018 | 9 | 0.150 |
Why?
|
| Tobacco Use Disorder | 1 | 2019 | 90 | 0.140 |
Why?
|
| Sex Characteristics | 1 | 2019 | 174 | 0.140 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2019 | 97 | 0.140 |
Why?
|
| Cell Proliferation | 3 | 2019 | 604 | 0.140 |
Why?
|
| Cyclization | 2 | 2008 | 2 | 0.140 |
Why?
|
| Argininosuccinate Synthase | 1 | 2018 | 2 | 0.140 |
Why?
|
| Electrochemistry | 2 | 2008 | 14 | 0.140 |
Why?
|
| Arginine | 1 | 2018 | 18 | 0.140 |
Why?
|
| Models, Biological | 2 | 2018 | 392 | 0.140 |
Why?
|
| Amino Acids | 1 | 2018 | 46 | 0.140 |
Why?
|
| Cell Differentiation | 2 | 2017 | 469 | 0.130 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2017 | 3 | 0.130 |
Why?
|
| Interleukin-13 Receptor alpha2 Subunit | 1 | 2017 | 11 | 0.130 |
Why?
|
| Biological Transport | 1 | 2017 | 68 | 0.130 |
Why?
|
| Urea | 1 | 2017 | 37 | 0.130 |
Why?
|
| Sarcoma | 1 | 2018 | 71 | 0.130 |
Why?
|
| Quinolines | 1 | 2017 | 21 | 0.130 |
Why?
|
| Liposomes | 1 | 2017 | 30 | 0.130 |
Why?
|
| Substrate Specificity | 1 | 2017 | 81 | 0.130 |
Why?
|
| Molecular Imaging | 1 | 2017 | 20 | 0.130 |
Why?
|
| Ethylamines | 1 | 2016 | 2 | 0.130 |
Why?
|
| Receptor, Serotonin, 5-HT2C | 1 | 2016 | 2 | 0.130 |
Why?
|
| Receptor, Serotonin, 5-HT2A | 1 | 2016 | 3 | 0.130 |
Why?
|
| DNA Damage | 1 | 2017 | 94 | 0.130 |
Why?
|
| Cell Communication | 1 | 2017 | 29 | 0.130 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2017 | 55 | 0.130 |
Why?
|
| Protein Binding | 1 | 2017 | 201 | 0.130 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2016 | 23 | 0.130 |
Why?
|
| Peptide Fragments | 1 | 2019 | 410 | 0.130 |
Why?
|
| Pericytes | 1 | 2016 | 33 | 0.120 |
Why?
|
| Medical Oncology | 1 | 2017 | 92 | 0.120 |
Why?
|
| Mice, Transgenic | 2 | 2016 | 259 | 0.120 |
Why?
|
| Stem Cell Transplantation | 1 | 2016 | 212 | 0.110 |
Why?
|
| Liver | 1 | 2017 | 492 | 0.100 |
Why?
|
| Cognition | 1 | 2017 | 553 | 0.100 |
Why?
|
| Radionuclide Imaging | 1 | 2013 | 26 | 0.100 |
Why?
|
| Metabolic Clearance Rate | 1 | 2013 | 17 | 0.100 |
Why?
|
| Obesity | 1 | 2020 | 1179 | 0.100 |
Why?
|
| Organ Specificity | 1 | 2013 | 80 | 0.100 |
Why?
|
| Kidney | 1 | 2017 | 523 | 0.100 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 241 | 0.090 |
Why?
|
| Middle Aged | 3 | 2025 | 12203 | 0.090 |
Why?
|
| Muscle, Skeletal | 1 | 2016 | 537 | 0.090 |
Why?
|
| Sensitivity and Specificity | 1 | 2013 | 576 | 0.090 |
Why?
|
| Stereoisomerism | 2 | 2008 | 20 | 0.090 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 770 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 599 | 0.080 |
Why?
|
| Macaca mulatta | 2 | 2022 | 319 | 0.070 |
Why?
|
| Benzilates | 1 | 2008 | 2 | 0.070 |
Why?
|
| Mandelic Acids | 1 | 2008 | 2 | 0.070 |
Why?
|
| Hydroxylation | 1 | 2008 | 5 | 0.070 |
Why?
|
| Fluorenes | 1 | 2008 | 4 | 0.070 |
Why?
|
| Indoles | 1 | 2008 | 56 | 0.070 |
Why?
|
| Models, Chemical | 1 | 2007 | 31 | 0.070 |
Why?
|
| Quinolones | 1 | 2007 | 7 | 0.070 |
Why?
|
| Reference Standards | 1 | 2007 | 32 | 0.070 |
Why?
|
| Salts | 1 | 2007 | 1 | 0.070 |
Why?
|
| Imines | 1 | 2007 | 2 | 0.070 |
Why?
|
| Electrons | 1 | 2007 | 12 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2012 | 950 | 0.070 |
Why?
|
| Treatment Outcome | 2 | 2025 | 3460 | 0.070 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2017 | 115 | 0.060 |
Why?
|
| Adult | 1 | 2019 | 9586 | 0.060 |
Why?
|
| Aged | 3 | 2025 | 10637 | 0.060 |
Why?
|
| Cerebrospinal Fluid | 1 | 2025 | 18 | 0.060 |
Why?
|
| Atrophy | 1 | 2025 | 46 | 0.060 |
Why?
|
| Double-Blind Method | 1 | 2025 | 543 | 0.050 |
Why?
|
| Predictive Value of Tests | 1 | 2025 | 894 | 0.050 |
Why?
|
| Self Administration | 1 | 2022 | 293 | 0.040 |
Why?
|
| Protein Transport | 1 | 2020 | 72 | 0.040 |
Why?
|
| Eating | 1 | 2020 | 74 | 0.040 |
Why?
|
| Ethanol | 1 | 2022 | 191 | 0.040 |
Why?
|
| Ketone Bodies | 1 | 2019 | 8 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2019 | 98 | 0.040 |
Why?
|
| Cyclosporine | 1 | 2019 | 49 | 0.040 |
Why?
|
| Cerebrovascular Circulation | 1 | 2019 | 96 | 0.040 |
Why?
|
| Radiochemistry | 1 | 2018 | 1 | 0.040 |
Why?
|
| Risk | 1 | 2019 | 316 | 0.040 |
Why?
|
| Lymph Nodes | 1 | 2019 | 114 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2019 | 94 | 0.040 |
Why?
|
| Amino Acid Transport System y+ | 1 | 2018 | 1 | 0.040 |
Why?
|
| Cell Line | 1 | 2019 | 436 | 0.030 |
Why?
|
| Hydrolases | 1 | 2018 | 5 | 0.030 |
Why?
|
| Quinazolines | 1 | 2018 | 38 | 0.030 |
Why?
|
| Polyethylene Glycols | 1 | 2018 | 64 | 0.030 |
Why?
|
| Memory | 1 | 2019 | 191 | 0.030 |
Why?
|
| Cell Membrane | 1 | 2018 | 97 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2019 | 566 | 0.030 |
Why?
|
| Cysteamine | 1 | 2017 | 2 | 0.030 |
Why?
|
| Copper Radioisotopes | 1 | 2017 | 3 | 0.030 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2017 | 16 | 0.030 |
Why?
|
| X-Ray Microtomography | 1 | 2017 | 41 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2017 | 64 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2025 | 4065 | 0.030 |
Why?
|
| Colorectal Neoplasms | 1 | 2019 | 222 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2019 | 754 | 0.030 |
Why?
|
| Antigens | 1 | 2016 | 31 | 0.030 |
Why?
|
| Peptides | 1 | 2017 | 126 | 0.030 |
Why?
|
| Proteoglycans | 1 | 2016 | 29 | 0.030 |
Why?
|
| Cell Lineage | 1 | 2016 | 71 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2025 | 3708 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2016 | 80 | 0.030 |
Why?
|
| Brain Mapping | 1 | 2017 | 179 | 0.030 |
Why?
|
| Cell Separation | 1 | 2016 | 90 | 0.030 |
Why?
|
| Gene Expression | 1 | 2017 | 336 | 0.030 |
Why?
|
| Neovascularization, Physiologic | 1 | 2016 | 111 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2016 | 290 | 0.030 |
Why?
|
| Cell Movement | 1 | 2016 | 173 | 0.030 |
Why?
|
| Phenotype | 1 | 2016 | 644 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 2014 | 99 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2016 | 790 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 1015 | 0.030 |
Why?
|
| Time Factors | 1 | 2017 | 2195 | 0.020 |
Why?
|
| Phenol | 1 | 2007 | 9 | 0.020 |
Why?
|